# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): August 5, 2022

# TONIX PHARMACEUTICALS HOLDING CORP.

(Exact name of registrant as specified in its charter)

Nevada (State or Other Jurisdiction of Incorporation)

001-36019 (Commission File Number)

26-1434750 (IRS Employer Identification No.)

26 Main Street, Chatham, New Jersey 07928 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (862) 904-8182

Check the appropriate box below if the Form General Instruction A.2. below):	3-K filing is intended to simultaneously satisfy the fil	ling obligation of the registrant under any of the following provisions (see
	under the Exchange Act (17 CFR 240.14a-12) ant to Rule 14d-2(b) under the Exchange Act (17 CFR ant to Rule 13e-4(c) under the Exchange Act (17 CFR	\ //
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	TNXP	The NASDAQ Capital Market
Emerging growth company □  If an emerging growth company, indicate by claccounting standards provided pursuant to Sect		extended transition period for complying with any new or revised financial
	Incorporation or Bylaws; Change in Fiscal Year.	tendment to its Articles of Incorporation, as amended, with the Secretary of
State of the State of Nevada to increase the num	nber of authorized shares of the Company's common s	stock from 50,000,000 to 150,000,000 shares (the "Charter Amendment").

### the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.01 to this Current Report on Form 8-K and incorporated in this Item 5.03 by reference.

Submission of Matters to a Vote of Security Holders.

The Company's shareholders approved two proposals at the Special Meeting. Shareholders representing (i) 15,904,924 shares, or 50.2%, of the Company's common stock, each of which is entitled to one vote per share, (ii) 2,500,000 shares of the Company's Series A Convertible Redeemable Preferred Stock (the "Series A"), each of which is entitled to 2.5 votes per share, for an aggregate of 6,250,000 votes, and (iii) 500,000 shares of the Company's Series B Convertible Redeemable Preferred Stock (the "Series B"), each of which is entitled to 2.500 votes per share, for an aggregate of 1,250,000,000 votes, outstanding as of the June 28, 2022 record date were represented at the Special Meeting by proxy. The holders of the Series A have agreed to vote in favor of the Charter Amendment, and the holders of the Series B have agreed to vote in a manner that mirrors the vote of the common stock and Series A. The proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on July 5, 2022, pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended.

on August 5, 2022 (the "Special Meeting"). The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to

#### Proposal 1

Item 5.07.

The Company's shareholders approved an amendment to the Company's Articles of Incorporation, as amended, to increase the Company's authorized shares of common stock from 50,000,000 to 150,000,000, as set forth below:

Votes For	Votes Against	Abstentions	Broker Non-Votes
967,282,625	301,428,310	3,443,989	N/A

		oved a proposal the adjournme il 1, as set forth below:	nt of the Special Meeting, if necessary, if a quo	rum is present, to solicit additional proxies if there are not	
Votes For		Votes Against	Abstentions	Broker Non-Votes	
10,691,946 4,973,617		4,973,617	239,361	N/A	
Item 9.01	Financial State	ments and Exhibits.			
(d)	Exhibit No.		Description.		
	3.01		f Nevada on August 5, 2022	articles of Incorporation, as amended, filed with the Secretary	
			SIGNATURE		
Pursi duly authorize		ent of the Securities Exchange A	act of 1934, the registrant has duly caused this re	port to be signed on its behalf by the undersigned thereunto	
			TONIX PHARMACEU	TICALS HOLDING CORP.	
Date: August	5, 2022		By: <u>/s/ Bradley Saenge</u> Bradley Saenger Chief Financial Officer	ur	

### BARBARA K. CEGAVSKE

Secretary of State

#### KIMBERLEY PERONDI

Deputy Secretary for Commercial Recordings

#### STATE OF NEVADA



OFFICE OF THE SECRETARY OF STATE

Commercial Recordings Division 202 N. Carson Street Carson City, NV 89701 Telephone (775) 684-5708 Fax (775) 684-7138

North Las Vegas City Hall 2250 Las Vegas Bhd North, Suite 400 North Las Vegas, NV 89030 Telephone (702) 486-2880 Fax (702) 486-2888

### **Certified Copy**

8/5/2022 8:55:11 AM

 Work Order Number:
 W2022080500218

 Reference Number:
 20222531345

 Through Date:
 8/5/2022 8:55:11 AM

Corporate Name: TONIX PHARMACEUTICALS

HOLDING CORP.

The undersigned filing officer hereby certifies that the attached copies are true and exact copies of all requested statements and related subsequent documentation filed with the Secretary of State's Office, Commercial Recordings Division listed on the attached report.

Document Number	Description	Number of Pages
20222531340	Amendment After Issuance of Stock	3

Certified By: Rhonda Tuin

Certificate Number: B202208052905602

You may verify this certificate online at <a href="http://www.nvsos.gov">http://www.nvsos.gov</a>

Respectfully,

BARBARA K. CEGAVSKE Nevada Secretary of State



BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Filed in the Office of

Boulum K. (egassle)

Secretary of State

State Of Nevada

Business Number
E0792182007-8
Filing Number
20222531340
Filied On
8/5/2022 8:16:00 AM
Number of Pages
3

# **Profit Corporation:**

Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390)
Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403)

Officer's Statement (PURSUANT TO NRS 80.030)

1. Entity information:	Name of entity as on file with the Nevada Secretary of State:			
	Tonix Pharmaceuticals Holding Corp.			
	Entity or Nevada Business Identification Number (NVID):	E0792182007-8		
2. Restated or Amended and Restated Articles: (Select one) (If amending and restating only, complete section 1,2 3, 5 and 6)	Certificate to Accompany Restated Articles or Amended and Restated Articles  Restated Articles - No amendments; articles are restated only and are signed by an officer of the corporation who has been authorized to execute the certificate by resolution of the board of directors adopted on:  The certificate correctly sets forth the text of the articles or certificate as amended to the date of the certificate.  Amended and Restated Articles  * Restated or Amended and Restated Articles must be included with this filling type.			
3. Type of Amendment Filing Being Completed:  Certificate of Amendment to Articles of Incorporation (Pursuant to NRS 78.3)  The undersigned declare that they constitute at the state of th				
(Select only one box) (If amending, complete section 1, 3, 5 and 6.)	following:  (Check only one box)  incorporators  board of directors  The undersigned affirmatively declare that to the date of this certificate, no stock of the corporation has been issued			
	Certificate of Amendment to Articles of Incorporation (Pursuant to NRS 78.385 and 78.390 - After Issuance of Stock)  The vote by which the stockholders holding shares in the corporation entitling them to exercise at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, or as may be required by the provisions of the articles of incorporation* have voted in favor of the amendment is:  More than 50%  Officer's Statement (foreign qualified entities only) - Name in home state, if using a modified name in Nevada:			
	Jurisdiction of formation:  Changes to takes the following effect:  The entity name has been amended.  The purpose of the entity has been amended.  The authorized shares have been amended.  Other: (specify changes)	Dissolution		

This form must be accompanied by appropriate fees.

creation.

Page 1 of 2 Revised: 1/1/2019



BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov

### **Profit Corporation:**

Certificate of Amendment (PURSUANT TO NRS 78.380 & 78.385/78.390)

## Certificate to Accompany Restated Articles or Amended and Restated Articles (PURSUANT TO NRS 78.403)

Officer's Statement (PURSUANT TO MRS 80 030)

		3 Statement (PORSU)		
4. Effective Date and	Date:		Time:	
Time: (Optional)		(must not be later than 9	0 days after the certificate is filed)	
5. Information Being	Changes to takes	the following effect:		
Changed: (Domestic	The entity name has been amended.			
corporations only)	☐ The registered agent has been changed. (attach Certificate of Acceptance from new			
	registered agent)			
	☐ The purpose of the entity has been amended.			
	The authorized shares have been amended.			
	The dire	ectors, managers or general par	tners have been amended.	
	☐ IRS tax	language has been added.		
	200	have been added.		
		have been deleted.		
	Other.			
	The articles have been amended as follows: (provide article numbers, if available)			
	Article IV has been amended as set forth below and on Annex A.			
	(attach additional page(s) if necessary)			
6. Signature:	x BRa	2	Chief Financial Officer	
(Required)		fficer or Authorized Signer	Title	
	X			
	Signature of C	Officer or Authorized Signer	Title	
	*If any proposed amendment would alter or change any preference or any relative or other right given to any class or series of outstanding shares, then the amendment must be approved by the vote, in addition to			
	the affirmative vote otherwise required, of the holders of shares representing a majority of the voting power			
	of each class or series affected by the amendment regardless to limitations or restrictions on the voting power thereof.			
		ny required or optional inform	nation in space below:	
		(attach additional page(s) if neces		
Article IV has been	amended to inc	crease the authorized shar	es of common stock to 150,00	00,000.
The complete text of	of Article IV, as	amended, is as follows:		
			n is authorized to issue two cla	
			\$0.001. The second class of	STOCK
shall be Preferred S	stock, par value	\$0.001.		
(continues on Anne	ex A)			
This form must be according				Dana 2 of

# TONIX PHARMACEUTICALS HOLDING CORP. CERTIFICATE OF AMENDMENT

### **ANNEX A**

The Preferred Stock, or any series thereof, shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be expressed in the resolution or resolutions providing for the issue of such stock adopted by the board of directors and may be made dependent upon facts ascertainable outside such resolution or resolutions of the board of directors, provided that the matter in which such facts shall operate upon such designations, preferences, rights and qualifications; limitations or restrictions of such class or series of stock is clearly and expressly set forth in the resolution or resolutions providing for the issuance of such stock by the board of directors.

The total number of shares of stock of each class which the Corporation shall have authority to issue and the par value of each share of each class of stock are as follows:

Class	Par Value	Α	uthorized Shares
Common	\$0.001		150,000,000
Preferred	\$0.001		5,000,000
		Total:	155,000,000